SGMOQ
What one share of Sangamo Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases.
Sangamo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.11 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.28 |
| Cash and investments | $0.07 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.53 | −$0.44 | $0.01 | −$0.15 | — | $1.70 |
| 2010 | $0.46 | −$0.55 | $0.02 | −$0.55 | — | $1.23 |
| 2011 | $0.20 | −$0.71 | $0.01 | −$0.52 | — | $1.52 |
| 2012 | $0.41 | −$0.42 | $0.01 | −$0.17 | — | $1.22 |
| 2013 | $0.43 | −$0.48 | $0.01 | −$0.36 | — | $1.96 |
| 2014 | $0.68 | −$0.39 | $0.01 | −$0.09 | — | $2.99 |
| 2015 | $0.57 | −$0.58 | $0.03 | −$0.52 | — | $2.74 |
| 2016 | $0.27 | −$1.02 | $0.01 | −$0.94 | — | $1.92 |
| 2017 | $0.47 | −$0.70 | $0.05 | $0.10 | — | $2.20 |
| 2018 | $0.87 | −$0.70 | $0.44 | −$0.07 | — | $3.59 |
| 2019 | $0.91 | −$0.85 | $0.18 | −$1.47 | — | $3.73 |
| 2020 | $0.88 | −$0.90 | $0.11 | $1.15 | — | $3.51 |
| 2021 | $0.77 | −$1.23 | $0.16 | −$1.77 | — | $2.57 |
| 2022 | $0.72 | −$1.25 | $0.13 | −$1.58 | — | $1.77 |
| 2023 | $1.01 | −$1.48 | $0.12 | −$1.41 | — | $0.47 |
| 2024 | $0.29 | −$0.49 | $0.00 | −$0.33 | — | $0.11 |
| 2025 | $0.14 | −$0.44 | $0.00 | −$0.35 | — | −$0.04 |